Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Eccles, Ron ^a   Meier, Christiane ^b   Jawad, Martez ^a   Weinmüllner, Regina ^b   Grassauer, Andreas ^b   Prieschl Grassauer, Eva ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Marinomed Biotechnologie GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ANTIHISTAMINIC AGENT; CARRAGEENAN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; IBUPROFEN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; PLACEBO; SODIUM CHLORIDE; ANTIVIRUS AGENT; AUTACOID;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; COMMON COLD; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; EYE SWELLING; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; MYALGIA; NASAL LAVAGE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SNEEZING; VIRUS LOAD; VOMITING; AEROSOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; NOSE MUCUS; TIME; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIVIRAL AGENTS; CARRAGEENAN; COMMON COLD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; NASAL LAVAGE FLUID; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77956682296     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-108     Document Type: Article

References (25)

1. Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev 2009,
2. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005, 5:718-725. 10.1016/S1473-3099(05)70270-X, 16253889.
3. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003, 163:487-494. 10.1001/archinte.163.4.487, 12588210.
4. Heikkinen T, Jarvinen A. The common cold. Lancet 2003, 361:51-59. 10.1016/S0140-6736(03)12162-9, 12517470.
5. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold - high cost to society. Allergy 2009, 65(6):776-83. 10.1111/j.1398-9995.2009.02269.x, 19958315.
6. Footitt J, Johnston SL. Cough and viruses in airways disease: mechanisms. Pulm Pharmacol Ther 2009, 22:108-113. 10.1016/j.pupt.2008.12.022, 19480062.
7. Jefferson TO, Tyrrell D. Antivirals for the common cold. Cochrane Database Syst Rev 2001, CD002743.
8. Di RM. Biological properties of carrageenan. J Pharm Pharmacol 1972, 24:89-102.
9. US Food and Drug Administration Generally Recognized as Safe (GRAS). US Food and Drug Administration., http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/default.htm
10. Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol J 2008, 5:107. 10.1186/1743-422X-5-107, 2562995, 18817582.
11. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007, 363:473-485. 10.1016/j.virol.2007.01.043, 17337028.
12. Gonzalez ME, Alarcon B, Carrasco L. Polysaccharides as antiviral agents: antiviral activity of carrageenan. Antimicrob Agents Chemother 1987, 31:1388-1393. 174948, 2823697.
13. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006, 2:e69. 10.1371/journal.ppat.0020069, 1500806,1500806, 16839203.
14. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med 1958, 101:267-278.
15. South East Wales Local Research Ethics Committee. , http://www.nres.npsa.nhs.uk/contacts/find-your-local-rec/
16. MedRA MSSO The medical dictionary for regulatory activities. MedRA MSSO., http://meddramsso.com/
17. Rabago D, Pasic T, Zgierska A, Mundt M, Barrett B, Maberry R. The efficacy of hypertonic saline nasal irrigation for chronic sinonasal symptoms. Otolaryngol Head Neck Surg 2005, 133:3-8. 10.1016/j.otohns.2005.03.002, 16025044.
18. Rabago D, Zgierska A, Mundt M, Barrett B, Bobula J, Maberry R. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract 2002, 51:1049-1055.
19. Kassel JC, King D, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev 2010, 3:CD006821.
20. Onari Y, Yokoyama A, Haruta Y, Nakashima T, Iwamoto H, Hattori N, et al. IL-12p40 is essential for the down-regulation of airway hyperresponsiveness in a mouse model of bronchial asthma with prolonged antigen exposure. Clin Exp Allergy 2009, 39:290-298. 10.1111/j.1365-2222.2008.03131.x, 19032358.
21. Tregoning JS, Schwarze J. Respiratory Viral Infections in Infants: Causes, Clinical Symptoms, Virology, and Immunology. Clinical Microbiology Reviews 2010, 23:74-98. 10.1128/CMR.00032-09, 20065326.
22. Rohde G. Drug targets in rhinoviral infections. Infect Disord Drug Targets 2009, 9:126-132.
23. Peltola V, Waris M, Osterback R, Susi P, Ruuskanen O, Hyypia T. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008, 197:382-389. 10.1086/525542, 18248302.
24. Peltola V, Jartti T, Putto-Laurila A, Mertsola J, Vainionpaa R, Waris M, et al. Rhinovirus infections in children: a retrospective and prospective hospital-based study. J Med Virol 2009, 81:1831-1838. 10.1002/jmv.21590, 19697407.
25. Patick AK. Rhinovirus chemotherapy. Antiviral Res 2006, 71:391-396. 10.1016/j.antiviral.2006.03.011, 16675037.